Literature DB >> 15660538

Regression to the mean: treatment effect without the intervention.

Veronica Morton1, David J Torgerson.   

Abstract

Regression to the mean (RTM) is a widespread statistical phenomenon. It is a group phenomenon that occurs whenever an extreme group is selected from a population based on the measurement of a particular variable. If a second measurement is then taken for the same group, the second mean will be closer to the population mean than the first measurement. This decrease (or increase) can be mistakenly attributed to a treatment effect; the conclusion can be drawn that an effect results from treatment when it in fact results from chance. Any intervention that is aimed at a group or characteristic that is very different from the average will appear to be successful because of RTM. It is therefore important that any genuine reductions because of the treatment are separated out from the effect of RTM. If the problem is ignored then this will lead to errors in the interpretation of results and, potentially, decisions made on the evidence of those results. This paper highlights the importance of the issue and its effects on many common clinical, public health and managerial decisions.

Mesh:

Year:  2005        PMID: 15660538     DOI: 10.1111/j.1365-2753.2004.00505.x

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  31 in total

1.  Use of randomised trials to decide when to monitor response to new treatment.

Authors:  Katy J L Bell; Les Irwig; Jonathan C Craig; Petra Macaskill
Journal:  BMJ       Date:  2008-02-16

2.  Confusing placebo effect with natural history in epilepsy: A big data approach.

Authors:  Daniel M Goldenholz; Robert Moss; Jonathan Scott; Sungyoung Auh; William H Theodore
Journal:  Ann Neurol       Date:  2015-07-29       Impact factor: 10.422

3.  The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.

Authors:  Luca Durelli; Pierangelo Barbero; Mauro Bergui; Elisabetta Versino; Marco A Bassano; Elisabetta Verdun; Bruno Ferrero; Chiara Rivoiro; Cinzia Ferrero; Elisabetta Picco; Paolo Ripellino; Daniela Viglietti; Giorgio Giuliani; Enrico Montanari; Marinella Clerico
Journal:  J Neurol       Date:  2008-09-25       Impact factor: 4.849

Review 4.  Response to placebo in clinical epilepsy trials--Old ideas and new insights.

Authors:  Daniel M Goldenholz; Shira R Goldenholz
Journal:  Epilepsy Res       Date:  2016-02-10       Impact factor: 3.045

5.  Evidence Base Update of Psychosocial Treatments for Self-Injurious Thoughts and Behaviors in Youth.

Authors:  Catherine R Glenn; Erika C Esposito; Andrew C Porter; Devin J Robinson
Journal:  J Clin Child Adolesc Psychol       Date:  2019-05-02

6.  Evaluation of Sex Positive! A Video eHealth Intervention for Men Living with HIV.

Authors:  Sabina Hirshfield; Martin J Downing; Mary Ann Chiasson; Irene S Yoon; Steven T Houang; Richard A Teran; Christian Grov; Patrick S Sullivan; Rachel J Gordon; Donald R Hoover; Jeffrey T Parsons
Journal:  AIDS Behav       Date:  2019-11

7.  Efficacy of standardised manual therapy and home exercise programme for chronic rotator cuff disease: randomised placebo controlled trial.

Authors:  Kim Bennell; Elin Wee; Sally Coburn; Sally Green; Anthony Harris; Margaret Staples; Andrew Forbes; Rachelle Buchbinder
Journal:  BMJ       Date:  2010-06-08

8.  Shared medical appointments based on the chronic care model: a quality improvement project to address the challenges of patients with diabetes with high cardiovascular risk.

Authors:  Susan Kirsh; Sharon Watts; Kristina Pascuzzi; Mary Ellen O'Day; David Davidson; Gerald Strauss; Elizabeth O Kern; David C Aron
Journal:  Qual Saf Health Care       Date:  2007-10

9.  A multi-dataset time-reversal approach to clinical trial placebo response and the relationship to natural variability in epilepsy.

Authors:  Daniel M Goldenholz; Alex Strashny; Mark Cook; Robert Moss; William H Theodore
Journal:  Seizure       Date:  2017-10-23       Impact factor: 3.184

Review 10.  Montelukast in the treatment of allergic rhinitis: an evidence-based review.

Authors:  Anjuli Nayak; Ronald B Langdon
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.